Semiannual Securities Report — FY2026 H1
What Astellas Pharma Inc. reported for the period from 2026-04-01 to 2026-09-30.
Filed 2026-11-06View the original on EDINET
How much it says
53Typical
What moved here
14named for the first time
Its own wording
15terms
Which filing this is
38/ 38newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period, the company newly entered into a technology in-licensing agreement with Vir Biotechnology relating to ASP6958 (VIR-5500), and also entered into a settlement and amendment to the licensing agreement with MSN Pharmaceuticals and MSN Laboratories. In addition, “stricter quality-related regulations” and “the increasingly complex geopolitical and regulatory environment surrounding US-China relations,” among others, were added as global risks.
Komori's summary of this document, not the document's own words.53Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
61
Detailed
56
Typical
38
Thin
0
Almost nothing
68
Detailed
55
Typical
62
Detailed
53
Typical
55
Typical
50
Typical
R&D spend1,677億円Money spent making new things.
Cash left over188億円Cash from the business, less what went into equipment.
Spent on equipment247億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.